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BACKGROUND: The influence of human prolactin (hPRL) on the development of breast and other types of cancer is well established.
Little information, however, exists on the effects of hPRL on squamous cell carcinomas of the head and neck (SCCHNs).
METHODS: In this study, we evaluated prolactin receptor (PRLR) expression in SCCHN cell lines and assessed by
immunohistochemistry the expression in 89 patients with SCCHNs. The PRLR expression was correlated with clinicopathological
characteristics as well as clinical outcome. The effect of hPRL treatment on tumour cell growth was evaluated in vitro.
RESULTS: Immunoreactivity for PRLR was observed in 85 out of 89 (95%) tumours. Multivariate COX regression analysis confirmed
high levels of PRLR expression (425% of tumour cells) to be an independent prognostic factor with respect to overall survival
(HR¼3.70, 95% CI: 1.14–12.01; P¼0.029) and disease-free survival (P¼0.017). Growth of PRLR-positive cancer cells increased in
response to hPRL treatment.
CONCLUSION: Our data indicate that hPRL is an important growth factor for SCCHN. Because of PRLR expression in a vast majority of
tumour specimens and its negative impact on overall survival, the receptor represents a novel prognosticator and a promising drug
target for patients with SCCHNs.
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The neuroendocrine hormone prolactin (PRL) has been shown to
promote growth and differentiation of several organs in verte-
brates, including breast, ovaries and prostate (Hennighausen et al,
1997; Ahonen et al, 1999; Russell and Richards, 1999). In addition,
human PRL (hPRL) plays an important role in physiological and
pathological processes of the squamous epithelium of the human
skin and can influence hair follicle growth and keratinisation
(Foitzik et al, 2009; Ramot et al, 2010). Several studies have
provided epidemiological data indicating involvement of hPRL in
cancer development, specifically in breast, prostate and, as recently
shown by our group, colorectal cancer (Tworoger et al, 2007;
Harvey et al, 2008; Tworoger and Hankinson, 2008; Harbaum et al,
2010).
A series of experimental studies corroborate the role of hPRL in
cancer biology. Upon binding to the prolactin receptor (PRLR),
hPRL activates PRLR-associated Janus kinase 2 (Jak2), which in
turn activates signal transducers and activators of transcription
(Stats) (Hennighausen et al, 1997). The PRLR-activated Stats
promote the growth of human prostate cancer cells by regulation
of Bcl-XL and cyclin D and the survival of breast cancer cells via
induction of HSP90A (Dagvadorj et al, 2008; Perotti et al, 2008). In
addition to this classical PRLR-dependent signal transduction
pathway, PRLR exerts tumour-promoting effects by activating
numerous other molecular mechanisms. These include autocrine
stimulation via the Jak-2/Stat5a/b pathway in prostate cancer
(Dagvadorj et al, 2007), crosstalk with the PI3K/mTor pathway in
lymphoma cells (Bishop et al, 2006), induction of vascular
endothelial growth factor (Goldhar et al, 2005) and synergism
with the insulin-like growth factor I receptor in breast cancer
(Carver et al, 2010). Thus, given the widespread expression of
PRLR in cancer, its interaction with several known signal
transduction pathways and the availability of PRLR antagonists
(Scotti et al, 2008; Tomblyn et al, 2009), PRLR represents an
attractive drug target. Whereas the involvement of hPRL and its
receptor in skin physiology and various cancer types is well
documented, little is known about the role of this hormone in the
pathogenesis of squamous cell carcinomas of the head and neck
(SCCHNs). An initial observation connecting circulating hPRL
with the development of SCCHNs came from an early report by
Bhatavdekar et al (1993). In this study, hyperprolactinemia proved
to be an independent predictor of short-term prognosis in tongue
cancer patients. In a larger trial conducted by the same group,
hPRL serum levels in patients with advanced tongue cancer were
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ssignificantly higher compared with control subjects, and hPRL
serum levels were identified as an independent prognostic factor
for overall patient survival (Bhatavdekar et al, 2000). In contrast to
these data, Meyer et al (2010) recently reported that circulating
serum hPRL levels did not significantly predict outcome in a study
of 527 patients with SCCHNs. Data regarding the role of circulating
hPRL in the growth and progression of SCCHNs are contradictory,
and data concerning the role of PRLR in SCCHN tissues are
currently not available. Therefore, we evaluated the role of hPRL
and its receptor in the pathogenesis of SCCHNs. The hypothesis
tested was that hPRLR could be a potential drug target. We used
immunohistochemistry (IHC) to determine the prevalence of
PRLR expression in SCCHN tissue samples and assessed PRLR
expression in SCCHN cell lines by immunocytochemistry, flow
cytometry and immunoprecipitation. In addition, we correlated
the PRLR expression in tissue samples with clinicopathological
parameters and disease-free and overall survival data. Finally, we
determined the effects of hPRL treatment on growth of SCCHN
cells in vitro.
MATERIALS AND METHODS
Cell lines
The human breast cancer cell line T47D was obtained from the
American Type Culture Collection (Manassas, VA, USA) and was
maintained in RPMI-1640 medium (Life Technologies, Inc., Grand
Island, NY, USA) supplemented with 10% (v/v) fetal bovine
serum (FBS), 1mM glutamine, 100Uml
–1 penicillin and
100mgml
–1 streptomycin (Life Technologies, Inc.). All other
tumour cell lines studied were established from patients with
SCCHNs at the University of Pittsburgh and were maintained in
our laboratory, as described previously (Heo et al, 1989). Detailed
characteristics of the primary tumours (designated as A) and the
corresponding metastatic lesions (designated as B) are listed in
Table 1. Before the proliferation assays, the PCI-6A and PCI-6B cell
lines and the T47D cell line were cultured in DMEM and RPMI-
1640 supplemented with 10% charcoal-stripped (CSS) FBS for 1
week, respectively. Charcoal stripping of heat-inactivated FBS was
performed using 1.5g dextran-coated charcoal (Sigma, St Louis,
MO, USA) for every 100ml FBS, with stirring overnight at 41C. The
charcoal-stripped FBS was then centrifuged at 14000r.p.m. for
20min at 41C, and the supernatant was recovered and sterilised
utilising a 0.2-mm pore size filter (Nalgene, Rochester, NY,
USA). FBS was stored at  201C until use. A similar procedure
removes at least 85% of endogenous lactogens in FBS (Biswas and
Vonderhaar, 1987).
Flow cytometry and immunocytochemistry
For measurement of PRLR expression on SCCHN cell lines, we
used an unlabelled protein-A-purified mouse anti-human PRLR
monoclonal antibody (mAb) B6.2 (Ab-1, Clone B6.2; Thermo
Fisher Scientific, Fremont, CA, USA). The specificity of this
reagent has been reported previously in the T47D cell line
(Banerjee et al, 1993). Details of flow cytometry and immunocy-
tochemistry methods are described in the Supplementary Informa-
tion online. The cells were analysed using FACScan (Becton
Dickinson, Mountain View, CA, USA) and Lysis II software. For
each sample, 10000 events were acquired, and the cell number and
mean fluorescence intensity were determined.
Immunoprecipitation
To investigate the specificity of PRLR antibody binding, we
performed PRLR immunoprecipitation using PCI-6A, PCI-6B and
T47D cells. For details of this analysis, please see also in the
Supplementary Information online.
Patients
The PRLR expression was assessed in tissues of two independent
patient cohorts. The preliminary study was performed using a
group of 13 SCCHN samples that were randomly selected from
tumour tissue archived in the Department of Pathology, University
of Pittsburgh, USA. In addition, tissue sections of the primary
tumour and lymph node metastases, from which the PCI-6A and
PCI-6B cell lines had been generated, were studied. Tissue staining
was performed as described previously (Mertani et al, 1998). All
tissues and human cell lines used in the experiments were obtained
from consenting subjects under the IRB approval from the
University of Pittsburgh Cancer Institute.
To evaluate the prognostic value of PRLR expression in SCCHN
and to further substantiate the results of our preliminary study, a
larger cohort containing 89 SCCHN specimens was studied using
tumour tissue archived at the biobank of the Medical University
Graz, Austria. This retrospective study included randomly selected
patients diagnosed with SCCHN in the oral cavity between January
1992 and December 2002. For each specimen, both primary
tumour tissue and clinicopathological data were available. Patients
did not receive neoadjuvant therapy, and all underwent curative
resection. The median follow-up period was 5.8 years. For each
patient, postoperative surveillance was performed including
routine clinical and laboratory examination every 3 months, and
CT scans of the head and neck as well as X-rays of the chest every 6
months. After 5 years, intervals were extended to 12 months. The
6th edition of the American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (UICC) TNM system was used
to classify the patients. The characteristics of the patients are
shown in Table 2.
Immunohistochemistry
We performed immunohistochemistry using a tissue microarray
(TMA) technique, as described previously (Kononen et al, 1998).
Briefly, TMAs were constructed using a manual tissue-arraying
instrument (Beecher, Silver Spring, MD, USA). To account for
tumour heterogeneity, three cylindrical core biopsies, 0.6mm in
diameter, were excised from various sites within each tumour and
arrayed on a recipient paraffin TMA block. The TMA sections
(4mm) were stained using an automated staining system (Bench-
MarkTM; Ventana Medical Systems, SA, Illkirch, CEDEX, France).
Tissue digestion was performed using Protease Type I
(0.5unitsml
–1; catalogue no. 760-2018, Ventana) for 32min. The
primary PRLR antibody (Ab-1, Clone B6.2; Thermo Fisher
Scientific) was applied in a 1:400 dilution, and the reaction was
visualised using the ultraVIEW Universal DAB Detection KitTM
(catalogue no. 760-500; Ventana). Immunoreactivity was indepen-
dently assessed by two experienced pathologists (CL and AA), who
were blinded to clinicopathological data, using a semiquantitative
scoring system. Discrepancies were resolved by simultaneous
Table 1 Pathological characteristics of the primary and metastatic
squamous cell carcinomas of the head and neck from which the respective
cell lines were generated
Cell line Tumour/metastatic site Differentiation
PCI-4A Larynx Moderate
PCI-4B Neck node Moderate
PCI-6A Tonsil Well–moderate
PCI-6B Neck node Poor
PCI-15A Piriform sinus Poor
PCI-15B Lymph node Poor
PCI-37A Larynx Well–moderate
PCI-37B Lymph node Well–moderate
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sre-examination on the slides by both investigators using a double-
headed microscope. Membranous and/or granular cytoplasmic
staining was considered positive, and immunoreactivity was
semiquantitatively categorised as follows: focal (o25% of tumour
cells), moderate (25–75% of tumour cells) or extensive (475%).
For analysing the prognostic value of PRLR expression in SCCHNs,
we defined the focal expression pattern as the low PRLR expression
group and summarised tumours with moderate and extensive
PRLR expression to a high PRLR expression group. Each tumour
was scored assessing the average positivity of the core biopsies.
Samples of breast cancer tissue known to express PRLR served as
positive control. Negative controls included omission of the
primary antibody and incubation with the Ventana Antibody
Diluent (catalogue no. 251-018).
MTT assay
Tumour cell lines were cultured in the presence or absence
of various concentrations of hPRL at 20, 40 or 100ngml
–1;
kindly provided by Dr AF Parlow, National Hormone & Peptide
Program (Torrance, CA, USA). Cell proliferation was measured
using the colorimetric MTT (3-(4,5-dimethylthiazal-2-yl)-2,5-
diphenyltetrazolium bromide) assay, as previously described (Lin
et al, 1995).
Statistical analysis
All statistical analyses were performed using SPSS version 17.0
software (SPSS Inc., Chicago, IL, USA). The Fisher’s exact test,
w
2 test and the Mann–Whitney procedure were used to analyse
PRLR expression in relation to each clinicopathological parameter.
The disease-free and overall survival of the patients were
calculated using the Kaplan–Meier method and compared by the
log-rank test. Backward stepwise Cox proportion analysis was
performed to determine the influence of PRLR expression, T and N
classification, tumour grade, patient age and gender on overall and
disease-free survival. Hazard ratios (HRs) estimated from Cox
models were reported as relative risks with corresponding 95%
confidence intervals (CIs). The assumption of proportional
hazards was checked by LML plots and residual analysis using
Schoenfeld plots. A P-value of o0.05 was considered significant.
RESULTS
PRLR expression in SCCHN cell lines
The PRLR expression was initially assessed in SCCHN cell lines
(n¼8) established from primary tumours and the corresponding
metastases from four patients. The breast cancer cell line T47D
served as the positive control. The PRLR expression was
determined in the SCCHN lines by flow cytometry and immuno-
cytochemistry. Of the eight SCCHN lines, five (4A, 4B, 6A, 37A,
37B) were positive for PRLR expression (Table 3). The only pair of
SCCHN cell lines with a heterogeneous PRLR expression profile
was PCI-6A and PCI-6B (Figure 1A). The majority of PCI-6A cells,
which had been generated from a primary tumour, were highly
PRLR positive, whereas all PCI-6B cells generated from a
metachronously developed corresponding lymph node metastasis
were negative for PRLR, both on the cell surface and in the
cytoplasm (Figure 1B). To substantiate the specificity of PRLR
staining results, we examined PRLR expression in the SCCHN cell
lines PCI-6A and PCI-6B using immunoprecipitation. In accor-
dance with data obtained from immunocytochemistry and flow
cytometry, PRLR immunoprecipitation resulted in a prominent
band at 80kDa that corresponded to the PRLR-predicted
molecular weight using lysate from PCI-6A cells, whereas only a
weak band was detected in PCI-6B cell lysate (Figure 1C). To
exclude the possibility that the divergent PRLR expression profiles
of PCI-6A and PCI-6B cells might be because of culture selection,
we evaluated PRLR expression in sections of the primary tumour
and the metachronously developed lymph node metastasis by
immunohistochemistry (Figure 2). The results from these samples
confirmed the data obtained from the cell lines. To further validate
the results obtained with the SCCHN lines, we examined 13 tissue
specimens of primary and metastatic SCCHNs randomly selected
from the institutional tumour tissue archive. Breast tissue speci-
mens known to express PRLR served as control. Of 13 SCCHN
specimens, 9 (69%) were positive for PRLR expression based on
Table 3 Surface and intracytoplasmatic expression of the PRLR on four
pairs of squamous cell carcinoma lines generated from the primary tumour
and autologous lymph node metastases
a
PRLR surface
expression
PRLR intracellular
expression
ICC
Cell line % Pos. cells MFI % Pos. cells MFI
PCI-4A 1 17 7 19 Pos
PCI-4B 6 38 16 21 Pos
PCI-6A 58 633 51 475 Pos
PCI-6B 1 48 1 38 Neg
PCI-15A 0 0 5 67 Neg
PCI-15B 0 0 2 80 Neg
PCI-37A 26
b 26
b 96 27 Pos
PCI-37B 82 640 95 435 Pos
Abbreviations: PRLR¼prolactin receptor; MFI¼mean fluorescence intensity;
ICC¼immunocytochemistry; Pos.¼positive.
aData were obtained by flow cytome-
try of dissociated monolayers or by ICC of cytocentrifuged cells.
bAfter trypsinization
that led to considerable loss of PRLR surface expression but cells could not be
detached from culture flask otherwise.
Table 2 Clinicopathological characteristics of the SCCHN patients
included in this study
Clinicopathological parameters Patients (n¼89) Proportion
Gender
Male 67 75%
Female 22 25%
Median age at diagnosis
Male 56 (37–88)
Female 65 (40–88)
Tumour size
T1 37 41%
T2 21 24%
T3 10 11%
T4 21 24%
Nodal status
N0 60 67%
N1 14 16%
N2 15 17%
Grade
G1 18 20%
G2 46 52%
G3 25 28%
Stage
I 34 38%
II 16 18%
III 12 14%
IV 27 30%
Abbreviation: SCCHN¼squamous cell carcinoma of the head and neck.
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sthe intensity of PRLR staining and the distribution of positive cells
(data not shown).
PRLR expression and correlation with clinicopathological
parameters and patients’ outcome
To evaluate whether PRLR expression is associated with the
outcome of patients with SCCHN, we determined PRLR expression
by immunohistochemistry in a larger set of human SCCHN
tumour samples. Expression of PRLR was observed in 89 primary
tumours with 8 (9%) cases showing focal, 16 (18%) moderate and
65 (73%) extensive immunoreactivity, respectively (Figure 3).
Median follow-up was 70 months (mean 73, range 1–202). The
5-year disease-free survival was observed in 43 (48%) patients, 46
(52%) patients developed disease recurrence including 6 (7%)
patients who developed distant metastasis and 41 (46%) died
during a 5-year follow-up period. A comparison of the moderate
PRLR expression group (25–75%) with the extensive PRLR
expression group (475%) showed no differences for clinical
outcome in the univariate analysis. Therefore, we compared focal
expression (o25%) (categorised to the PRLR low expression
group) vs moderate and/or extensive expression (categorised to the
PRLR high expression group) and found that a higher degree of
PRLR expression was associated with decreased disease-free and
overall survival. After a cutoff value of 25% positive tumour cells
had been identified as the strongest discriminator for patient
outcome, all subsequent analyses used this value, and we defined
tumours showing o25% PRLR-positive tumour cells as the PRLR
low expression group and tumours showing 425% PRLR-positive
tumour cells as the PRLR high expression group. Over the
complete follow-up period, the rate of disease recurrence (75 vs
38%, Po0.05), including distant metastases (7 vs 0%), was higher
in the PRLR high expression group compared with the PRLR low
expression group. Also, 58 out of 81 (72%) patients with tumours
with high PRLR expression and 3 out of 8 (38%) patients with
tumours showing low PRLR expression died during the follow-up
period (P¼0.023, log-rank test; Figure 4A). Disease-free survival
after 5 years was documented in 36 out of 81 (44%) patients with
tumours with high PRLR expression and 7 out of 8 (87%) patients
with tumours showing low PRLR expression (P¼0.017, log-rank
test, Figure 4B). Furthermore, T and N classification, both known
to define a poor prognosis in SCCHNs, were significantly
associated with disease-free and overall survival (data not shown).
No association between PRLR expression and clinicopathological
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Figure 1 PRLR expression in SCCHN cell lines. (A) PRLR expression measured by flow cytometry in PCI-6A, PCI-6B and T47D cell lines. The PCI-6A cell
line shows a significantly higher percentage of PRLRþ cells compared with the PCI-6B cell line. (B) Immunocytochemical staining of SCCHN cell lines
(magnification  400). Positive membranous and cytoplasmic PRLR staining (red colour of Cy3) is shown for the PCI-6A cell line, whereas the PCI-6B cell
line is negative. Nuclei are counterstained with Hoechst dye (blue). (C) Immunoprecipitation reveals a prominent band between 75 and 80kD,
corresponding to the PRLR protein in the lysate of PCI-6A cells, whereas only a weak band was detected in the lysate of PCI-6B cells. Immunoglobulin G
(IgG) heavy chain was used as a loading control and T47D cell line served as a positive control.
Figure 2 PRLR expression in SCCHN tissues. In agreement with the corresponding cell lines PCI-6A and PCI-6B, the primary tumour (A) shows PRLR
positivity, whereas the metachronously developed neck lymph node metastasis (B) is PRLR negative.
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sparameters, such as T and N classification as well as tumour
differentiation, gender and age, was observed (Table 4). To
determine the independent prognostic value of PRLR expression
on patients’ outcome, a multivariate analysis using a Cox
proportional hazard model was performed. In Cox’s proportional
hazards regression models including PRLR expression, T and N
classification, tumour grade, as well as patient age and gender, we
identified advanced tumour stages (stage I and II vs III and IV;
HR¼1.78, 95% CI: 1.03–3.05; P¼0.034), nodal positive disease
(nodal negative vs nodal positive disease; HR¼2.20, 95% CI: 1.30–3.75;
P¼0.003) and high PRLR immunoreactivity (low vs high
expression group; HR¼3.70, 95% CI: 1.14–12.01; P¼0.029) as
independent prognostic variables with respect to overall survival.
For the other parameters tested, no independent influence on
outcome was observed.
hPRL effects on PCI-6A, PCI-6B and T47D cell growth
The MTT assay was used to investigate the effects of hPRL on
PRLR-positive PCI-6A and PRLR-negative PCI-6B cell growth
when cultured in media supplemented with CSS FBS with and
without the addition of hPRL. The T47D breast cancer cell line
served as positive control. We observed a moderate, although
statistically significant, hPRL-dependent increase in the growth of
T47D cells and PCI-6A cells when compared with untreated cells
(Po0.01 and Po0.04, respectively). A 20% increase in the growth
was observed for the 20ngml
–1hPRL concentration with a decline
at the highest concentrations of the hormone (100ngml
–1). The
hPRL treatment did not affect the growth of PRLR-negative PCI-6B
cells (data not shown).
DISCUSSION
It has been known for decades that hPRL, a peptide hormone
secreted by the anterior pituitary, is a potential growth and
differentiation factor for mammary epithelium. Evidence from
numerous in vivo and in vitro studies has linked this classical
hormone to a series of other physiological processes. Thus, hPRL
may be synthesised as a paracrine/autocrine cytokine, and
expression of its receptor is not restricted to the mammary gland
Figure 3 Immunohistochemistry for PRLR in SCCHN tissues. (A) Note low PRLR expression level in normal tissue and well-differentiated tumour tissue,
and high PRLR expression level in poorly differentiated tumour tissue ( 100). (B) PRLR expression on representative SCCHN spots on the TMA
comprising three paired spots (columns) from four different tumours (lines). Note the variable PRLR immunoreactivity between different tumours (lines)
and the high concordance between different cores from the same tumour (columns).
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Figure 4 Kaplan–Meier plots for overall survival (A) and disease-free survival (B) in patients with SCCHNs with low vs high PRLR expression.
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s(Ben-Jonathan et al, 1996; Dorshkind and Horseman, 2000).
Beyond the physiological effects of this circulating hormone, a
substantial number of studies focussed on the importance of hPRL
in cancer biology (Ben-Jonathan et al, 2002; Clevenger, 2003). This
approach is promising as PRLR inhibition could serve as a novel
strategy for the treatment of cancer (Clevenger et al, 2008). To
date, several lines of evidence suggest the involvement of the
hPRL/PRLR axis in breast, prostate and colorectal cancer
development (McHale et al, 2008; Harbaum et al, 2010). However,
the role of hPRL in SCCHNs remains largely unknown. A recent
study reported that the serum prolactin level was not a prognostic
factor for predicting outcome in a large cohort of SCCHN patients
(Meyer et al, 2010). Given the negative findings between
circulating hPRL and prognosis in SCCHNs, we decided to study
the expression of PRLR within SCCHN cancer tissue. There are
three main findings in this study concerning hPRL/PRLR and
SCCHNs: (1) PRLR is widely expressed in SCCHNs; (2) high level
of PRLR expression is an independent negative prognostic factor
for overall survival in patients with SCCHNs; and (3) hPRL acts as
a growth factor for PRLR-expressing SCCHN cancer cells. We
found that 490% of primary tumours included in our study were
positive for PRLR, but its expression was variable, ranging from
very low to high. Patients expressing high levels of PRLR had a
significantly lower overall survival. To our knowledge, only two
other studies have addressed the presence of PRLR in SCCHNs. In
the first, Patel et al (1994) reported on PRLR expression in 25 male
patients with advanced tongue cancer. Similar to our study, the
authors found no correlation between PRLR status and any of the
tested clinicopathological variables. They reported PRLR negativ-
ity in 17 patients with hyperprolactinaemia as an independent
predictor for short-term prognosis. However, they used a different
cutoff level for PRLR positivity and included only 25 patients in
their study, which may have been insufficient to detect clinically
significant differences. In the second study, PRLR measured by a
ligand binding assay and by PRLR mRNA using RT–PCR were
detectable in 8 out of 24 (33%) and 41 out of 50 (82%) of tumour
samples, respectively. However, follow-up data, including clinical
outcome, were not available in that investigation (Bhatavdekar
et al, 2000). Our study shows for the first time that in a large
cohort of patients, PRLR expression in tumour tissues is
significantly associated with a decreased survival in SCCHN
patients. We identified 25% positive tumour cells as a cutoff value
for optimal discrimination between good and poor prognosis.
However, this threshold should undergo external validation in
large prospective studies, as one limitation of our study is the
relative small number of patients in the PRLR low expression
group. The molecular mechanisms underlying this result have yet
to be clarified. Bhatavdekar et al (2000) detected hPRL protein and
mRNA expression in 44 and 85% of SCCHN patients, respectively,
and proposed a role for hPRL as a local growth promoter.
However, there is currently no study available that investigates the
influence of hPRL on the growth of SCCHN cancer cells generated
from primary tumours and their corresponding metastases.
Therefore, we selected a PRLR-positive and a negative cell line to
determine the effects of hPRL on cell growth. Both the T47D breast
cancer line and the PRLR-positive PCI-6A SCCHN cell line showed
a moderate but significant increase of cell growth in the presence
of hPRL. Similar to many cytokines that induce receptor
dimerisation, hPRL exhibited a bell-shaped curve rather than a
linear dose-response relationship; this is in agreement with
previous reports using other cell lines (Fuh and Wells, 1995;
Hooghe et al, 1998). This observation supports the hypothesis that
hPRL might act as a local paracrine/autocrine growth-promoting
factor in SCCHN. We found a significantly higher rate of local
disease recurrence and a higher rate of distant metastases in the
group with PRLR high expression. Therefore, it is reasonable to
hypothesise that tumours expressing higher levels of PRLR might
recur more frequently under the influence of local PRL exposure or
exhibit a more aggressive behaviour including development of
distant metastasis more frequently. In contrast to a lack of data for
SCCHNs, several studies have demonstrated that hPRL acts as a
growth factor for mammary epithelial cells (Clevenger et al, 2009).
For example, hPRL promotes survival of mammary epithelial cells
via activation of Akt 1 (Creamer et al, 2010). In addition, it
decreases the phosphorylation of serine residues on the PRLR,
thus impairing PRLR turnover and ultimately leading to
increased hPRL signalling (Plotnikov et al, 2009). Finally, hPRL
stimulates cell proliferation and migration by upregulation of
sphingosine kinase-1 expression (Doll et al, 2007). However, it
remains largely unknown whether these and other previously
proposed molecular mechanisms are relevant to SCCHNs. Never-
theless, our experiments suggest that PRLR has a potential as a
drug target in SCCHNs. Further experiments are necessary to
confirm this hypothesis. Traditional agents that block pituitary
hormone production do not affect extrapituitary hPRL expression.
Therefore, PRLR antagonists remain the most promising novel
drugs with the potential to disrupt hPRL/PRLR signalling.
Howell et al (2008) demonstrated that the PRLR antagonist
d1-9-G129R-hPRL potentiates the cytotoxicity of paclitaxel in
breast cancer cells. In a different study, it was shown that
hPRL confers resistance to cisplatin by upregulation of the
detoxification enzyme glutathione-S-transferase (LaPensee et al,
2009; Tomblyn et al, 2009). reported that three PRLR antagonist-
fusion proteins effectively prevented tumour recurrence and
development of distant metastases in a breast cancer xenograft
model, a strategy that has been successfully employed for PRLR-
expressing breast cancer cells (Langenheim and Chen, 2005;
Tomblyn et al, 2009). Hence, these inhibitors may also provide a
potential treatment strategy for patients with PRLR-positive
Table 4 Correlations between PRLR expression and clinicopathological
parameters
PRLR immunoreactivity
Clinicopathological
variables
PRLR low
expression
PRLR high
expression P-value
T classification
T1 2 (25%) 35 (43%) 0.511
T2 3 (37.5%) 18 (22%)
T3 1 (12.5%) 9 (11)
T4 2 (25%) 19 (24%)
N classification
N0 7 (87.5%) 53 (65%) 0.195
N1–3 1 (12.5%) 28 (35%)
Tumour grade
G1 3 (37.5%) 15 (19%) 0.404
G2 3 (37.5%) 43 (53%)
G3 2 (25%) 23 (28%)
Stage
I 2 (37.5%) 32 (40%) 0.868
II 3 (37.5%) 13 (16%)
III 1 (12%) 11 (14%)
IV 2 (25%) 25 (31%)
Gender
M 5 (62%) 62 (76%) 0.310
F 3 (38%) 19 (24%)
Age
o60 4 (50%) 44 (54%) 0.551
460 4 (50%) 37 (45%)
Abbreviation: PRLR¼prolactin receptor.
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cancer is beyond the scope of this article, we refer interested
readers to a recent excellent review by Carver et al (2009) for more
information. In conclusion, the present study indicates that PRLR
is widely expressed in SCCHNs and that high expression of PRLR
in tumour tissue is an independent negative prognostic factor for
overall survival in SCCHN patients. Furthermore, our data suggest
that human hPRL is a growth factor for SCCHNs and that it
promotes the proliferation of PRLR-positive cancer cells. Further
preclinical studies are warranted for the validation of PRLR as a
novel drug target in SCCHNs.
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